Delmestri, Antonella

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor–positive breast cancer: ATLAS, a randomised trial

Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet

Breast Cancer Treatment StudiesEstrogen and related hormone effects

Cited by 2,044

Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study

Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, G., Sena, A. G., Martinez-Hernandez, E., Delmestri, A., Verhamme, K., Rijnbeek, P. R., et al. (2021) · BMJ

Pharmacovigilance and Adverse Drug ReactionsSARS-CoV-2 and COVID-19 Research

Cited by 219

Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis

Li, X., Raventós, B., Roel, E., Pistillo, A., Martinez-Hernandez, E., Delmestri, A., Reyes, C., Strauss, V., Prieto-Alhambra, D., Burn, E., et al. (2022) · BMJ

SARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19

Cited by 118

Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID ‐19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries

Burn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., Duarte‐Salles, T., Fernandez‐Bertolin, S., Aragón, M., Reyes, C., et al. (2022) · Pharmacoepidemiology and Drug Safety

Heparin-Induced Thrombocytopenia and ThrombosisPharmacovigilance and Adverse Drug Reactions

Cited by 43

Data Resource Profile Update: CPRD GOLD

Sanchez-Santos, M. T., Axson, E. L., Dedman, D., & Delmestri, A. (2025) · International Journal of Epidemiology

Medical Coding and Health InformationElectronic Health Records Systems

Cited by 26